Research
Search
Close
Chen Libo
- Chief Physician, Doctoral Supervisor, Professor
- Department: Nuclear Medicine
- Research Area: Imaging and Nuclear Medicine (Nuclear Medicine)
- Research Interests: 131I Theranostics in Thyroid Carcinoma; Targeted Therapy of Radioiodine-refractory Thyroid Carcinoma; Personalized Treatment of Hyperthyroidism; Management of Bone Metastasis
- Contact: lbchen@sjtu.edu.cn
- Bachelor's degree from Medical College of Suzhou University, 1998
- Master's degree from Medical College of Suzhou University, 2003
- Doctoral degree from Shanghai Jiao Tong University School of Medicine, 2006
- Director, Department of Nuclear Medicine, Lingang Campus of Shanghai Sixth People's Hospital;
- Chairman, Thyroid Cancer Committee of Chinese Society of Clinical Oncology;
- Standing Member, Nuclear Medicine Committee of Chinese Society of Clinical Oncology
- Zhong P, Yang J, Wang Y, Wei L, Chen L#. Thyroid Accumulation of 99mTc-DTPA in Graves Disease. Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004858. Online ahead of print.PMID: 37703477（IF=10.6）
- Sa R, Liang R, Qiu X, He Z, Liu Z, Chen L#. Targeting IGF2BP2 Promotes Differentiation of Radioiodine Refractory Papillary Thyroid Cancer via Destabilizing RUNX2 mRNA. Cancers (Basel). 2022;14(5):1268. （IF=5.2）
- Sa R, Liang R, Qiu X, He Z, Liu Z, Chen L#. IGF2BP2-dependent activation of ERBB2 signaling contributes to acquired resistance to tyrosine kinase inhibitor in differentiation therapy of radioiodine-refractory papillary thyroid cancer. Cancer Lett. 2022;527:10-23.（IF=9.756）
- Cheng L, Sa R, Luo Q, Fu H, Jin Y, Tang L, Yang Y, Yu C, Chen L#. Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study. J Nucl Med. 2021;62(1):62-68. （IF=11.082）
- Sa R, Cheng L, Jin Y, Fu H, Shen Y, Chen L#. Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment. Front Endocrinol (Lausanne). 2020;11:587315.（IF=5.555）
- Cheng L, Fu H, Jin Y, Sa R, Chen L#. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study. Oncologist. 2020;25(4):e668-e678.（IF=5.55）
- Fu H, Cheng L, Sa R, Jin Y, Chen L#. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E?by synergistically decreasing global trimethylation of H3K27. J Cell Mol Med. 2020;24(6):3336-3345.（IF=5.31）
- Jin Y, Liu M, Sa R, Fu H, Cheng L, Chen L#. Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics. Cancer Lett. 2020;469:35-53. （IF=8.679）
- Jin Y, Ruan M, Cheng L, Fu H, Liu M, Sheng S, Chen L#. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial. Thyroid. 2019;29(1):101-110.（IF=5.227）
- Ruan M, Liu M, Dong Q, Chen L#. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(5):1771-1779. （IF=6.31）
- 01/01/2022-12/31/2025
National Natural Science Foundation of China (Key Program), ¥55,0000, 82171981
Role: Project leader - 01/01/2017-12/31/2020
National Natural Science Foundation of China (Key Program), ¥55,0000, 81671711
Role: Project leader - 01/01/2013-12/31/2016
National Natural Science Foundation of China (Key Program), ¥55,0000, 81271609
Role: Project leader
- [Chen Li] (2016),“Application of a system for the treatment of hyperthyroidism”, CN 105447335 B; ZL 20161 0014778.7
